Hhlr Advisors, Ltd. Beam Therapeutics Inc. Transaction History

Hhlr Advisors, Ltd.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $98.5 Million - $143 Million	-1,448,161 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$84.37 - $133.6 $33.5 Million - $53.1 Million	-397,592 Reduced 21.54%	1,448,161 $126 Million
Q2 2021 Aug 16, 2021	SELL	$64.12 - $128.71 $14.6 Million - $29.2 Million	-226,926 Reduced 10.95%	1,845,753 $238 Million
Q1 2021 May 17, 2021	SELL	$71.28 - $120.75 $63.7 Million - $108 Million	-893,724 Reduced 30.13%	2,072,679 $166 Million
Q1 2020 May 15, 2020	BUY	$13.31 - $29.2 $39.5 Million - $86.6 Million	2,966,403 New	2,966,403 $53.4 Million

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.82B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Hhlr Advisors, Ltd. with notifications on news.